Literature DB >> 21300031

Dose-dependent differential effects of risedronate on gene expression in osteoblasts.

J Wang1, P H Stern.   

Abstract

Bisphosphonates have multiple effects on bone. Their actions on osteoclasts lead to inhibition of bone resorption, at least partially through apoptosis. Effects on osteoblasts vary, with modifications in the molecule and concentration both resulting in qualitatively different responses. To understand the mechanism of the differential effects of high and low bisphosphonate concentrations on osteoblast activity, we compared the effects of 10⁻⁸ M and 10⁻⁴ M risedronate on gene expression in UMR-106 rat osteoblastic cells. Two targeted arrays, an 84-gene signaling array and an 84-gene osteogeneic array were used. Gene expression was measured at 1 and 24 h. Although some genes were regulated similarly by low and high concentrations of the drug, there was also differential regulation. At 1 h, 11 genes (1 signaling and 10 osteogenesis) were solely regulated by the low concentration, and 7 genes (3 signaling, 4 osteogenesis) were solely regulated by the high concentration. At 24 h, 8 genes (3 signaling, 5 osteogenesis) were solely regulated by the low concentration and 30 genes (16 signaling and 14 osteogenesis) were solely regulated by the high concentration. Interestingly, the low, but not the high concentration of risedronate transiently and selectively upregulated several genes associated with cell differentiation. A number of genes related to apoptosis were regulated, and could be involved in effects of bisphosphonates to promote osteoblast apoptosis. Also, observed gene changes associated with decreased angiogenesis and decreased metastasis could, if they occur in other cell types, provide a basis for the effectiveness of bisphosphonates in the prevention of cancer metastases.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21300031      PMCID: PMC3480331          DOI: 10.1016/j.bcp.2011.01.025

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  54 in total

1.  Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.

Authors:  F P Coxon; M H Helfrich; R Van't Hof; S Sebti; S H Ralston; A Hamilton; M J Rogers
Journal:  J Bone Miner Res       Date:  2000-08       Impact factor: 6.741

2.  Calcium-mediated stress kinase activation by DMP1 promotes osteoblast differentiation.

Authors:  Asha Eapen; Premanand Sundivakkam; Yiqiang Song; Sriram Ravindran; Amsaveni Ramachandran; Chinnaswammy Tiruppathi; Anne George
Journal:  J Biol Chem       Date:  2010-09-14       Impact factor: 5.157

3.  Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.

Authors:  H L Benford; N W McGowan; M H Helfrich; M E Nuttall; M J Rogers
Journal:  Bone       Date:  2001-05       Impact factor: 4.398

Review 4.  The role of FasL and Fas in health and disease.

Authors:  Martin Ehrenschwender; Harald Wajant
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

5.  COMP-Ang1, a chimeric form of Angiopoietin 1, enhances BMP2-induced osteoblast differentiation and bone formation.

Authors:  Byung-Chul Jeong; Hyun-Joo Kim; In-Ho Bae; Kkot-Nim Lee; Kwang-Youl Lee; Won-Mann Oh; Sun-Hun Kim; In-Chol Kang; Shee-Eun Lee; Gou-Young Koh; Kyung-Keun Kim; Jeong-Tae Koh
Journal:  Bone       Date:  2009-09-25       Impact factor: 4.398

6.  IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts.

Authors:  Y Onoe; C Miyaura; T Kaminakayashiki; Y Nagai; K Noguchi; Q R Chen; H Seo; H Ohta; S Nozawa; I Kudo; T Suda
Journal:  J Immunol       Date:  1996-01-15       Impact factor: 5.422

7.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

8.  Identification of novel regulators associated with early-phase osteoblast differentiation.

Authors:  Diana S de Jong; Bart L T Vaes; Koen J Dechering; Alie Feijen; Jose M A Hendriks; Ron Wehrens; Christine L Mummery; Everardus J J van Zoelen; Wiebe Olijve; Wilma T Steegenga
Journal:  J Bone Miner Res       Date:  2004-02-20       Impact factor: 6.741

9.  Osteoblast proliferation and maturation by bisphosphonates.

Authors:  Gun-Il Im; Sheeraz A Qureshi; Jennifer Kenney; Harry E Rubash; Arun S Shanbhag
Journal:  Biomaterials       Date:  2004-08       Impact factor: 12.479

10.  Dominant negative Bmp5 mutation reveals key role of BMPs in skeletal response to mechanical stimulation.

Authors:  Andrew M Ho; Paul C Marker; Hairong Peng; Andres J Quintero; David M Kingsley; Johnny Huard
Journal:  BMC Dev Biol       Date:  2008-04-01       Impact factor: 1.978

View more
  1 in total

1.  Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells.

Authors:  R Thaler; S Spitzer; H Karlic; C Berger; K Klaushofer; F Varga
Journal:  Biochem Pharmacol       Date:  2012-10-24       Impact factor: 5.858

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.